Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Medtronic Atrial Fibrillation Solutions
Information provided by (Responsible Party):
Medtronic Atrial Fibrillation Solutions Identifier:
First received: October 19, 2011
Last updated: May 19, 2014
Last verified: May 2014

The Post-Approval Study (PAS) is a prospective multi-center, non-randomized, single arm, controlled,unblinded clinical study designed to provide long-term safety and effectiveness of the Arctic Front® Cardiac CryoAblation System.

Condition Intervention Phase
Paroxysmal Atrial Fibrillation (PAF)
Device: Medtronic Arctic Front® Cardiac CryoAblation System
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Sustained Treatment of Paroxysmal Atrial Fibrillation Post-Approval Study (STOP AF PAS)

Resource links provided by NLM:

Further study details as provided by Medtronic Atrial Fibrillation Solutions:

Primary Outcome Measures:
  • Effectiveness [ Time Frame: Through 36 months ] [ Designated as safety issue: No ]

    Evaluated by assessing the rate of subjects free of chronic treatment failure with paroxysmal atrial fibrillation who have failed one or more Atrial Fibrillation Drugs (AFDs).

    Chronic treatment failure is defined as:

    • Documented atrial fibrillation lasting longer than 30 seconds (outside the 90 day blanking period) OR
    • Intervention for atrial fibrillation (except for repeat cryoablation during the 90 day blanking period)

  • Safety [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
    Demonstrate safety (through 12 months) of Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor® MAX Cardiac Cryoablation Catheter by assessing the rate of subjects experiencing Cryoablation Procedure Events (CPEs) with paroxysmal atrial fibrillation who have failed one or more Atrial Fibrillation Drugs (AFDs).

Secondary Outcome Measures:
  • Chronic Safety [ Time Frame: Annually, through 5 years ] [ Designated as safety issue: Yes ]
    Freedom from Major Atrial Fibrillation Event (MAFE): A MAFE is a serious adverse event (SAE) which has not been categorized as a cryoablation procedure event.

  • Chronic Effectiveness [ Time Frame: Annually, through 5 years ] [ Designated as safety issue: No ]

    Freedom from chronic treatment failure, defined as:

    • Documented atrial fibrillation lasting longer than 30 seconds (outside the 90 day blanking period) OR
    • Intervention for atrial fibrillation (except for repeat cryoablation during the 90 day blanking period)

Estimated Enrollment: 400
Study Start Date: May 2012
Estimated Study Completion Date: January 2020
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Medtronic Arctic Front® Cardiac CryoAblation System
    Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
    Other Names:
    • Medtronic CryoCath CryoConsole
    • Arctic Front® Cardiac CryoAblation Catheter
    • Arctic Front Advance™ Cardiac CryoAblation Catheter
    • Freezor® MAX Cardiac CryoAblation Catheter
Detailed Description:

Safety and effectiveness will be evaluated against pre-specified performance criteria as determined by the sponsor and FDA. The criteria set in this study have been previously used to demonstrate safety and effectiveness in cryoablation and radio-frequency ablation for the treatment of paroxysmal atrial fibrillation.

The analyses of the primary effectiveness objective will take place once all the subjects with a study cryoablation procedure attempt have reached 36 months of follow-up post-cryoablation procedure. The analysis of the primary safety objective will take place once all the subjects with a study cryoablation procedure attempt have reached 12 months of follow-up post-cryoablation procedure. The analyses for the secondary objectives will take place once all subjects with a study cryoablation attempt have reached 60 months of follow-up post-cryoablation procedure.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Documented PAF:

    • Diagnosis of paroxysmal atrial fibrillation (PAF), AND
    • 2 or more episodes of AF during the 3 months preceding the consent Date, AND
    • At least 1 episode of AF documented with a tracing within 12 months preceding the consent date.
  2. Age 18 years or older
  3. Failure for the treatment of AF (effectiveness or intolerance) of at least one membrane active AAD for rhythm control.

Exclusion Criteria:

  1. Any previous left atrial (LA) ablation (except permissible retreatment subjects)
  2. Any previous LA surgery
  3. Current intracardiac thrombus (can be treated after thrombus is resolved)
  4. Presence of any pulmonary vein stents
  5. Presence of any pre-existing pulmonary vein stenosis
  6. Pre-existing hemidiaphragmatic paralysis
  7. Anteroposterior LA diameter > 5.5 cm by TTE
  8. Presence of any cardiac valve prosthesis
  9. Clinically significant mitral valve regurgitation or stenosis
  10. Myocardial infarction, PCI / PTCA or coronary artery stenting which occurred during the 3 month interval preceding the Consent Date
  11. Unstable angina
  12. Any cardiac surgery which occurred during the 3 month interval preceding the Consent Date
  13. Any significant congenital heart defect corrected or not (including atrial septal defects or pulmonary vein abnormalities but not including minor PFO)
  14. NYHA class III or IV congestive heart failure
  15. Left ventricular ejection fraction (LVEF) < 40%
  16. 2º (Type II) or 3º atrioventricular block
  17. Presence of a permanent pacemaker, biventricular pacemaker, atrial defibrillator or any type of implantable cardiac defibrillator (with or without biventricular pacing function)
  18. Brugada syndrome
  19. Long QT syndrome
  20. Arrhythmogenic right ventricular dysplasia
  21. Sarcoidosis
  22. Hypertrophic cardiomyopathy
  23. Known cryoglobulinemia
  24. Uncontrolled hyperthyroidism
  25. Any cerebral ischemic event (strokes or TIAs) which occurred during the 6 month interval preceding the Consent Date.
  26. Any woman known to be pregnant
  27. Life expectancy less than one (1) year
  28. Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of this study not pre-approved by Medtronic
  29. Unwilling or unable to comply fully with study procedures and followup
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01456949

  Hide Study Locations
United States, Alaska
Alaska Heart Institute Recruiting
Anchorage, Alaska, United States, 99508
Contact: Lori Heaney, RN    907-550-2283   
Principal Investigator: Steven Compton, MD         
United States, Arizona
Banner Good Samaritan Medical Center Recruiting
Phoenix, Arizona, United States, 85006
Contact: Kelly Dacanay    602-839-5674   
Principal Investigator: Wilber Su, MD         
United States, California
Good Samaritan Hospital Recruiting
San Jose, California, United States, 95124
Contact: Lori Henry, NP    408-879-5904   
Principal Investigator: Matthew Levy, MD         
United States, Colorado
Colorado Heart and Vascular Recruiting
Denver, Colorado, United States, 80204
Contact: Dana Long    303-629-2241   
Principal Investigator: Thomas Svinarich, MD         
United States, Florida
Daytona Heart Group Recruiting
Daytona Beach, Florida, United States, 32114
Contact: Nancy Mather    386-258-8722   
Principal Investigator: Hanscy Seide, MD         
Broward General Medical Center Recruiting
Fort Lauderdale, Florida, United States, 33316
Contact: Debra Ayer, MSN    954-355-5563   
Principal Investigator: Ahmed Osman, MD         
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Dana Leach, ARNP    352-273-8930   
Principal Investigator: William Miles, MD         
United States, Georgia
Emory University Hospital Recruiting
Atlanta, Georgia, United States, 30322
Contact: Deanna Hill, RN    404-727-4939   
Principal Investigator: Michael Lloyd, MD         
WellStar Kennestone Hospital Not yet recruiting
Marietta, Georgia, United States, 30060
Contact: Pamela Yaun    770-793-5975   
Principal Investigator: Jacob Blatt, MD         
United States, Illinois
Northwestern Memorial Hospital Recruiting
Chicago, Illinois, United States, 60611
Contact: Anna Huskin, RN BSN    312-695-4067   
Principal Investigator: Bradley Knight, MD         
United States, Indiana
Memorial Advanced Cardiovascular Institute Recruiting
South Bend, Indiana, United States, 46601
Contact: Kimberly Emmons    574-647-7883   
Principal Investigator: Raman Mitra, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Mai Doan    617-726-0280      
Principal Investigator: Moussa Mansour, MD         
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Deborah Manuelian    617-732-5087   
Principal Investigator: Roy John, MD         
United States, Minnesota
Metropolitan Cardiology Consultants PA Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: Stephanie Piche, RN    763-236-9167   
Principal Investigator: Stephen Remole, MD         
St. Mary's Hospital - Mayo Clinic Not yet recruiting
Rochester, Minnesota, United States, 55902
Contact: Kristi Monahan, RN    507-255-6676   
Principal Investigator: Douglas Packer, MD         
HealthEast St. Joseph's Hospital Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Joyce Riestenberg-Smith, RN    651-471-2671   
Principal Investigator: Stuart Adler, MD         
United States, Nebraska
Bryan LGH Recruiting
Lincoln, Nebraska, United States, 68506
Contact: Cheryl Orosco, RN BS    402-483-3291   
Principal Investigator: Andrew Merliss, MD         
United States, North Carolina
Asheville Cardiology Associate PA Recruiting
Asheville, North Carolina, United States, 28803
Contact: Jan Blakely, RN, BSN    828-274-6000 ext 393   
Principal Investigator: Joseph Souza, MD         
United States, Ohio
Bethesda North Hospital l TriHealth Hatton Institute Recruiting
Cincinnati, Ohio, United States, 45242
Contact: Nancy Firsich, RN    513-865-1148   
Principal Investigator: Gaurang Gandhi, MD         
United States, Oklahoma
Oklahoma Heart Institute Recruiting
Tulsa, Oklahoma, United States, 74104
Contact: Jolene Durham, RN    918-579-4939   
Principal Investigator: Craig Cameron, MD         
United States, Pennsylvania
Capital Cardiovascular Associates Recruiting
Camp Hill, Pennsylvania, United States, 17011
Contact: Joanna Stuck, RN BSN    717-724-6450 ext 1367   
Principal Investigator: Safwat Gassis, MD         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Susan Kilbride, MS    570-271-8492   
Principal Investigator: Jess Oren, MN         
Doylestown Cardiology Associates Recruiting
Doylestown, Pennsylvania, United States, 18901
Contact: Linda Schwarz, RN    215-933-0053   
Principal Investigator: Robert Sangrigoli, MD         
Lancaster Heart & Stroke Recruiting
Lancaster, Pennsylvania, United States, 17602
Contact: Holly Snyder, CMA    717-290-6681 ext 207   
Principal Investigator: Matthew Bernabei, MD         
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Dina Poole, RN    412-647-2931   
Principal Investigator: Sandeep Jain, MD         
United States, South Carolina
Columbia Heart Clinic Suspended
Columbia, South Carolina, United States, 29203
United States, Tennessee
Stern Cardiovascular Recruiting
Germantown, Tennessee, United States, 38138
Contact: Barbara Hamilton    901-271-4063   
Principal Investigator: Eric Johnson, MD         
Saint Thomas Research Institute Recruiting
Nashville, Tennessee, United States, 37205
Contact: Danielle Buchanan, RN    615-329-5144 ext 242   
Contact: Jane Jackson, MSN    615-222-3024   
Principal Investigator: James Baker, MD         
United States, Texas
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Anne Leyretana-Zabat    214-590-5015   
Principal Investigator: Richard Wu, MD         
Saint Luke's Episcopal Hospital - Texas Medical Center Recruiting
Houston, Texas, United States, 77030
Contact: Gilberto DeFreitas    832-355-4998   
Principal Investigator: John Seger, MD         
Baylor Research Institute Recruiting
Plano, Texas, United States, 75093
Contact: Gamar Rahimova    972-964-0363   
Principal Investigator: Brian DeVille, MD         
United States, Virginia
Inova Fairfax Hospital Recruiting
Fairfax, Virginia, United States, 22031
Contact: Christina Kim    703-776-8008   
Principal Investigator: Marc Wish, MD         
Canada, Alberta
Royal Alexandra Hospital Recruiting
Edmonton, Alberta, Canada
Contact: Sylvia Martin    780-735-4489   
Principal Investigator: Evan Lockwood, MD         
Canada, British Columbia
Vancouver General Hospital Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Contact: Daina Collet    604-875-5104   
Principal Investigator: Jason Andrade, MD         
Victoria Cardiac Arrhythmia Trials Inc Recruiting
Victoria, British Columbia, Canada
Contact: Fritha Munday, RN    250-595-0400   
Principal Investigator: Paul Novak, MD         
Canada, Quebec
Montreal Heart Institute Recruiting
Montreal, Quebec, Canada
Contact: Evelyne Naas    514-376-3330 ext 3309   
Principal Investigator: Marc Dubuc, MD         
Hôpital du Sacre Coeur de Montreal Recruiting
Montreal, Quebec, Canada
Contact: Ann Langlois, MS    514-338-2222   
Principal Investigator: Giuliano Becker, MD         
McGill University Health Centre Recruiting
Montreal, Quebec, Canada
Contact: Fiorella Rafti, BPharm PhD    514-934-1934 ext 42926      
Principal Investigator: Vidal Essebag, MD         
Institut Universitaire de Cardiologie et de Pneumologie de Québec Recruiting
Quebec, Canada
Contact: Brigitte Ottinger    418-656-8711 ext 3364   
Principal Investigator: Jean Champagne, MD         
Sponsors and Collaborators
Medtronic Atrial Fibrillation Solutions
Principal Investigator: Bradley P. Knight, MD, FACC, FHRS Northwestern Memorial Hospital
  More Information

No publications provided

Responsible Party: Medtronic Atrial Fibrillation Solutions Identifier: NCT01456949     History of Changes
Other Study ID Numbers: STOP AF PAS
Study First Received: October 19, 2011
Last Updated: May 19, 2014
Health Authority: United States: Institutional Review Board
Canada: Ethics Review Committee
Canada: Health Canada

Keywords provided by Medtronic Atrial Fibrillation Solutions:
Atrial fibrillation (AF)
Paroxysmal atrial fibrillation (PAF)
Cardiac Arrythmias
Cardiac ablation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on August 20, 2014